Parkman Healthcare Partners LLC Invests $21.40 Million in Stryker Corporation $SYK

Parkman Healthcare Partners LLC purchased a new stake in shares of Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 67,973 shares of the medical technology company’s stock, valued at approximately $21,401,000. Stryker accounts for about 2.2% of Parkman Healthcare Partners LLC’s holdings, making the stock its 14th largest position.

Other hedge funds have also recently bought and sold shares of the company. Gables Capital Management Inc. acquired a new stake in shares of Stryker during the second quarter worth approximately $25,000. Kilter Group LLC acquired a new position in Stryker in the 2nd quarter valued at approximately $25,000. Godfrey Financial Associates Inc. acquired a new position in Stryker in the 4th quarter valued at approximately $26,000. Sankala Group LLC purchased a new stake in Stryker in the 4th quarter worth approximately $26,000. Finally, Compass Financial Management LLC acquired a new stake in shares of Stryker during the 2nd quarter valued at $27,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Down 0.5%

SYK stock opened at $327.80 on Tuesday. The firm has a market cap of $125.73 billion, a PE ratio of 33.97, a PEG ratio of 2.10 and a beta of 0.76. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The company has a fifty day simple moving average of $327.39 and a 200 day simple moving average of $332.16. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the prior year, the business posted $3.13 earnings per share. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts anticipate that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio is currently 36.48%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Wolfe Research downgraded shares of Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. Raymond James Financial set a $370.00 price objective on Stryker in a research report on Friday, July 31st. Evercore set a $350.00 target price on Stryker in a research note on Monday, July 6th. Canaccord Genuity Group dropped their target price on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Finally, Leerink Partners cut their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Insider Activity

In related news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 355,370 shares of company stock valued at $119,447,201. Insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.